Solasia Pharma K.K (Salasia) and Nippon Kayaku (Nippon) have announced their joint license agreement for marketing rights for darinaparsin (SP-02) in Japan. Drug candidate developed by Salasia, darinaparsin, aims to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). Solasia has submitted a new drug application (NDA) with Japan’s Ministry of Health, Labour and Welfare in June 2021 and expects to launch in 2022 once received approval. According to the agreement, Solasia and Nippon Kayaku will work together to develop a new treatment option to patient suffering from PTCL.
Read more here.
More on: Health Healthcare News Regulatory
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.